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Nuclear receptor activation in liver leads to coordinated alteration of the expression of multiple gene
products with attendant phenotypic changes of hepatocytes. Peroxisome proliferators including endog-
enous fatty acids, environmental chemicals, and drugs induce a multi-enzyme metabolic response that
affects lipid and fatty acid processing. We studied the signaling network for the peroxisome prolifera-
tor-associated receptor alpha (PPARa) in primary human hepatocytes using the selective PPARa ligand,
GW7647. We measured gene expression over multiple concentrations and times and conducted ChIP-
seq studies at 2 and 24 h to assess genomic binding of PPARa. Over all treatments there were 192 genes
differentially expressed. Of these only 51% showed evidence of PPARa binding–either directly at PPARa
response elements or via alternative mechanisms. Almost half of regulated genes had no PPARa binding.
We then developed two novel bioinformatics methods to visualize the dose-dependent activation of both
the transcription factor circuitry for PPARa and the downstream metabolic network in relation to func-
tional annotation categories. Available databases identiﬁed several key transcription factors involved
with the non-genomic targets after GW7647 treatment, including SP1, STAT1, ETS1, ERa, and HNF4a.
The linkage from PPARa binding through gene expression likely requires intermediate protein kinases
to activate these transcription factors. We found enrichment of functional annotation categories for
organic acid metabolism and cell lipid metabolism among the differentially expressed genes. Lipid trans-
port processes showed enrichment at the highest concentration of GW7647 (10 lM). While our strategy
for mapping transcriptional networks is evolving, these approaches are necessary in moving from toxic-
ogenomic methods that derive signatures of activity to methods that establish pathway structure, show-
ing the coordination of the activated nuclear receptor with other signaling pathways.
 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Much of what we understand about responses to toxic com-
pounds comes from decades of experimentation in animal models.
This knowledge underwrites the safety regulations concerning
acceptable exposures to hazardous compounds in commercial,
industrial, and environmental applications. However, differencesbetween human biology and animal models make it difﬁcult to
deﬁnitively assess the safety of a compound from such studies.
Additionally, extrapolating from high-dose conditions typically
used for in-life animal testing to low-dose chronic exposures rele-
vant to human safety is complicated by nonlinear dose–response
relationships. A transition away from in-life toxicity testing to
mode of action-based testing is now underway to improve the
basis for inferring likely risks to humans from various chemicals
[1–3].
Perturbations induced by environmental chemicals often lead
to different physiological outcomes in humans and rodents, further
complicating extrapolation of animal test results for human risk
assessment [3]. For example, peroxisome proliferators including
endogenous fatty acids [4] and various synthetic ligands induce li-
pid metabolism enzymes in humans [5,6] and have been used suc-
cessfully as therapeutic strategies for various dyslipidemias and
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ence peroxisome assembly, inﬂammatory responses [7–9], and cel-
lular proliferation in addition to their role in regulating fatty acid
metabolism. Many peroxisome proliferators are potent carcino-
gens in rodents but do not appear to be carcinogenic in humans
[10,11].
Peroxisome proliferators act in both human and rodent cells
through the peroxisome proliferator-activated receptor (PPAR)
family of proteins. The three members of the PPAR family (a, c,
and d) are ligand-activated nuclear receptors. They mediate
highly context-speciﬁc gene transcription in response to environ-
mental or endogenous stimuli through a succession of steps
(Fig. 1). These steps include: (i) ligand-induced phosphorylation
of receptor in the cytosol; (ii) translocation of the receptor–ligand
complex to the nucleus; (iii) heterodimerization with binding
partners; (iv) binding of the heterodimer at DNA-response-ele-
ments in the promoters of target genes; and (v) recruitment of
co-activators and co-repressors, leading to altered gene expres-
sion. The three PPAR subtypes have tissue-speciﬁc expression,
and vary in the responses they mediate. PPARa is primarily ex-
pressed in the liver–where peroxisome proliferators induce can-
cer in rodents.
The canonical mechanism of PPARa-mediated response in-
volves the direct binding of activated PPARa to a well-established
consensus binding site, the peroxisome proliferator response ele-
ment (PPRE) [12,13]. However, changes in PPAR binding upon
treatment with exogenous ligands do not accurately predict
changes in gene expression [14]. Also, the majority of peroxisome
proliferator induced transcriptional changes are dampened or
eliminated in PPARa-deﬁcient cells for both mice and humansFig. 1. Identiﬁcation of the PPARa regulatory network. Three distinct mechanisms for
binding, and (iii) unbound non-genomic interactions.[15,16]. These facts indicate that mechanisms other than transacti-
vation by direct binding of PPARa to its cognate site must contrib-
ute to the effects of peroxisome proliferators, but that these
mechanisms depend on PPARa activity.
As a ﬁrst step in extending the canonical model of hormone
receptor regulation for PPARa, we describe here the response of
isolated human primary hepatocytes to the PPARa-speciﬁc exoge-
nous ligand GW7647 [17], and infer a transcriptional network
underlying the response. Recognizing the importance of the
dynamics of nuclear receptor biology, we collected dense dose
and time response gene expression data. We also functionally
characterize the genes differentially induced in the network at var-
ious doses of the ligand by their biological process annotation. Our
work has also produced several tools for visualizing network struc-
ture and gene-ontology dose response that should be widely useful
in establishing and characterizing signaling networks with other
nuclear receptors.2. Methods
2.1. Cell culture and treatment
Primary human hepatocytes were obtained from Invitrogen
(Carlsbad, CA). Cells were plated on Rat Collagen I-coated plates
and Geltrex was added for a ﬁnal concentration of 0.25 mg/ml
approximately 6 h after plating. Cells were maintained at 37 C in
a humidiﬁed 5% CO2 atmosphere in William E medium supple-
mented with cell maintenance cocktail B (Invitrogen). GW7647
was obtained from Tocris (Bristol, UK).regulating the targets of PPARa: (i) direct genomic binding, (ii) indirect genomic
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Total RNA was isolated using mirVANA kit by Ambion (Austin,
TX) according to manufacturer’s instructions. The RNA was diluted
in RNase-free H2O and quantiﬁed by Nanodrop (Thermo, Wilming-
ton, DE) at 260 nm. The quality of RNA samples was conﬁrmed
using RNA Nano Chips with Agilent 2100 Bioanalyzer (Agilent
Technologies, Waldbron, Germany). RNA samples were stored at
80 C until use.2.3. Microarray experiments and data analysis
From 5 lg total RNA, cDNA was synthesized using a one-cycle
cDNA synthesis kit (Affymetrix Corp., Santa Clara, CA). cDNA was
transcribed to cRNA which was then biotin-labeled using GeneChip
IVT labeling kit (Affymetrix). 15 lg labeled cRNAwere then hybrid-
ized to an Affymetrix Human Genome U133 Plus PM Array at 45 C
for 16 h. Biological cRNA replicates (n = 4) were each hybridized to
an individual array. After being washed using the GeneChip Fluid-
ics Station 450, arrays were scanned using a GeneTitan and inten-
sity values were extracted from the CEL ﬁle using Partek software
(St. Louis, MO). All gene expression data have been made publicly
available (GEO: GSE53399).2.4. Statistical analysis
Prior to performing data analysis, intensities were normalized
using robust multi-array average (RMA) method [18]. Evaluation
of the time- and dose-dependent effects of PPARa activation were
performed using two-way ANOVA with the Benjamini–Hochberg
false discovery rate controlling procedure [19]. Data with a false
discovery rate-corrected p 6 0.05 were considered signiﬁcant.2.5. Chromatin immunoprecipitation
The human hepatocytes used for chromatin immunoprecipita-
tion (ChIP) of PPARa were cultured from different donors than
those used for the gene expression microarray experiments. Hepa-
tocytes incubated with GW7647 or DMSO were ﬁxed with 1%
formaldehyde at room temperature for 15 min and quenched with
0.125 M glycine and shipped to Active Motif (Carlsbad, CA, USA) for
ChIP-seq analysis. Chromatin was isolated by adding lysis buffer,
followed by disruption with a Dounce homogenizer. Lysates were
sonicated using a Misonix Sonicator 3000 equipped with a microtip
in order to shear the DNA to an average length of 300–500 bp.
Lysates were cleared by centrifugation and stored at 80 C.
Genomic DNA (Input) was prepared by treating aliquots of
chromatin with RNase, proteinase K and heat for de-crosslinking,
followed by phenol/chloroform extraction and ethanol precipita-
tion. Puriﬁed DNA was quantiﬁed on a Nanodrop spectrophotome-
ter. Extrapolation to the original chromatin volume allowed
quantiﬁcation of the total chromatin yield.
For each ChIP reaction, 30 lg of chromatin was precleared with
protein A agarose beads (Invitrogen). ChIP reactions were set up
using precleared chromatin and antibody PPARa (sc-9000, Lot#
K2911) and incubated overnight at 4 C. Protein A agarose beads
were added and incubation at 4 C was continued for another
3 h. Immune complexes were washed two times each with a series
of buffers consisting of the deoxycholate sonication buffer, high
salt buffer, LiCl buffer, and TE buffer. Immune complexes were
eluted from the beads with SDS buffer, and subjected to RNase
treatment and proteinase K treatment. Crosslinks were reversed
by incubation overnight at 65 C, and ChIP DNA was puriﬁed by
phenol–chloroform extraction and ethanol precipitation.2.6. ChIP sequencing
ChIP and input DNAs were prepared for ampliﬁcation by con-
verting overhangs into phosphorylated blunt ends and adding an
adenine to the 30-ends. Illumina genomic adapters were ligated
and the sample was size-fractionated (200–250 bp) on a 2% aga-
rose gel. After a ﬁnal PCR ampliﬁcation step (18 cycles), the result-
ing DNA libraries were quantiﬁed and sequenced on HiSeq 2000.
Sequences (50 nucleotide reads, single end) were aligned to the hu-
man genome (hg19) using the BWA algorithm [20]. Aligns were ex-
tended in silico at their 30-ends to a length of 150 bp, which is the
average genomic fragment length in the size-selected library, and
assigned to 32-nt bins along the genome. Peak locations were
determined using the MACS algorithm (v1.4.2) with a cutoff of
p = 107 [21]. Signal maps and peak locations were used as input
data to Active Motif’s proprietary analysis program, which creates
excel tables containing detailed information on sample compari-
son, peak metrics, peak locations and gene annotations. Peaks were
assigned to genes with a transcription start site within 50 kb up- or
downstream (see Supplemental Text).2.7. De novo binding motif detection
MEME-ChIP was used for ab initio identiﬁcation of sequences
enriched in the sequenced ChIP fragments [22]. Binding sites were
compared to known binding sites in the Jaspar and UniPROBE dat-
abases using TOMTOM [23]. Motifs with expectation values greater
than 0.01 were considered signiﬁcantly enriched. The TRANSFAC
ExPlain module was used to identify ChIP intervals matching the
PPARa motif, controlling the false discovery rate at 0.05.3. Results
3.1. Transcriptional response by PPARa activation in primary
hepatocytes
We used microarray-based transcriptome proﬁling experiments
to identify gene targets whose expression changed as a conse-
quence of GW7647 treatment. mRNA from primary human hepato-
cytes isolated from four independent donors was collected at ﬁve
time points (2, 6, 12, 24, and 72 h) from cells treated with ﬁve con-
centrations of GW7647 between 0.001 and 10 lm. Over 54,000
probe sets representing more than 14,000 genes were evaluated
for this sampling of 25 different concentration and time conditions.
Only 192 genes were statistically signiﬁcantly up- or down-reg-
ulated upon treatment of GW7647 at any of the dose or time
points, with more than 80% showing up-regulation (Fig. 2B). These
up-regulated genes encompassed many lipid metabolism pathway
genes that are known targets of PPARa, including ACOX1 [24],
CPT1A [25,26], and APOA4 [27]. The differentially expressed genes
we identiﬁed correlate strongly with the set of genes regulated by
another PPARa-selective agonist, Wy14643 (Figure S1) [28]. The
relatively small number of differentially expressed genes was sur-
prising, but it is unlikely that higher doses or longer exposure time
would induce a substantial number of additional genes, as the con-
ditions we investigated were sufﬁcient to produce saturated dose
and time response and were well above the EC50 for PPARa activa-
tion by GW7647 (0.006 lM; [17]). The small number of differen-
tially expressed genes helped us develop our visualization tools
on a more manageable number of features before moving onto lar-
ger data sets, for instance with PPARa activation in rat hepatocytes,
where one expects many more genes are altered by treatment.
Transactivation of several of the differentially expressed target
genes by peroxisome proliferators results from binding of activated
PPARa at its cognate consensus promoter element, the peroxisome
A B
Fig. 2. Genomic response to GW7647. (A) Venn diagram summarizing ChIP and gene expression experiments. Regions not shown denote empty sets. Black arrow indicates
the set of genes that are up-regulated and associated with increased PPARa binding. Most peroxisome proliferator-induced expression changes are not associated with
increased binding of PPARa. Green arrow indicates genes that are associated with increased PPARa binding and decreased expression. (B) Matrix of 192 differentially
regulated genes. Rows are individual genes, organized according to mechanism of regulation. Columns are treatment conditions, increasing in dose from left to right.
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to which this canonical mechanism explains the gene expression
in primary human hepatocytes. Because no genome-wide study
of PPARa binding had previously been reported in primary human
hepatocytes, we used ChIP-seq to identify PPARa binding sites that
were not previously characterized.
We considered PPARa binding with and without activation by
GW7647 at 2 and 24 h of exposure. Long-range chromatin interac-
tions are important for nuclear receptors [29,30], complicating the
assignment of binding sites to their transcriptional targets. We
developed a novel statistical strategy for determining a reasonable
threshold for promoter length (see Supplemental Text). Here, we
deﬁne the promoter as the sequence bound within 50,000 bases
up and downstream of any transcription start site for the gene.
We identiﬁed 1766 binding sites mapping to the promoters of
1769 genes associated with increased PPARa binding, and 340
binding sites mapping to the promoters of 475 genes associated
with decreased binding (Fig. 2A). Of the 192 genes we identiﬁed
as differentially expressed, 98 were associated with a site with al-
tered PPARa binding. Interestingly, while there were 31 genes
down-regulated by GW7647, none of these were associated with
a decrease in PPARa binding.
We compared the results of our ChIP-seq study with results
from a ChIP-on-chip experiment studying the effect of the same li-
gand on PPARa binding in HepG2 human hepatoma cells [14] (Fig-
ure S2). Of the 3670 genes with enriched PPARa binding in HepG2
cells, only 46 (1.3%) mapped to our differentially expressed targets.
While some of this discrepancy may be due to differences in biol-
ogy between primary hepatocytes and immortalized hepatoma
cells, the authors of the previous study noticed a similar differencebetween PPARa-bound and differentially expressed genes in the
HepG2 line. The small number of differentially expressed genes
with direct or indirect association with PPARa suggests additional
layers of regulation beyond the traditional ligand-activated hor-
mone receptor model. This ﬁnding indicates that a substantial frac-
tion of genes affected by peroxisome proliferators are regulated by
mechanisms other than the classical model of nuclear receptor
biology.
In addition to direct binding of ligand-bound PPARa to its re-
sponse element, PPARa may inﬂuence the expression of target
genes through the formation of complexes with other transcription
factors – e.g. by ‘‘tethering’’ to other transcription factors that bind
directly to their cognate binding sites [31]. This group is the indi-
rectly bound targets (Fig. 1). Indeed, PPARa interacts with a large
number of other transcription factors and accessory proteins,
including Src, CBP/p300, and PGC1 [32]. Such complexes, when
they associate with DNA, are detectable by chromatin immunopre-
cipitation. To differentiate direct binding of PPARa to the promoter
from indirect binding through a coactivator, we performed a
computational search for PPREs within the enriched ChIP frag-
ments. 61 of 98 transcriptional targets bound by PPARa have direct
binding to a PPRE (Fig. 3A). These direct targets are on average
more strongly up-regulated than indirect targets, which are not
regulated by PPREs (Fig. 3B).
To validate these direct targets, we compiled a list of 11 of our
differentially expressed genes that have been shown in the litera-
ture to be direct targets of PPARa via low-throughput methods (Ta-
ble 1). For each of these targets, the location of a PPRE has been
experimentally identiﬁed via gel shift, low-throughput chromatin
immunoprecipitation (ChIP), ﬂuorescent reporter construct, or
AB
Fig. 3. Expression changes are more pronounced for direct and indirect genomic
targets. (A) Expression changes of the PPARa-bound targets as a function of dose
in cells treated for 24 h suggest a monotonic dose response. Genes are ordered
by expression change at the highest dose tested (10 lM). Directly bound targets
(blue text) have on average higher expression changes than do indirectly bound
targets (black text). (B) The expression changes of directly regulated targets is
higher than indirectly regulated targets (⁄p < 0.05, permutation test). Also,
indirectly regulated targets are more likely to have higher expression changes
than unbound targets.
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a comprehensive list of direct targets; there are certainly many
other sites with PPREs that have not been characterized to the de-
gree that these have. Of these targets, 8 were bound by PPARa at a
PPRE in response to GW7647 (Table 1). APOA2 and PLIN2 were
bound by PPARa at previously described sites [33,34], but these
sites were insufﬁciently similar to the PPREs we identiﬁed in other
binding sites to be classiﬁed as such. CYP1A1 had no differential
binding in response to GW7647 at the characterized site [35]–the
nearest binding site was 500,000 bases downstream of the gene.Table 1
Conﬁrmed direct targets of PPARa that are differentially expressed in human
bound by PPARa at the reported site; however our computational search d
PPARa at the reported sites in response to GW7647.
Symbol Name
ACOX1 Acyl-Coenzyme A oxidase 1, p
ANGPTL4 Angiopoietin-like 4
APOA2 Apolipoprotein A-II
APOA4 Apolipoprotein A-IV
CPT1A Carnitine palmitoyltransferase
CPT1B Carnitine palmitoyltransferase
CYP1A1 Cytochrome P450, family 1, su
FABP1 Fatty acid-binding protein 1
HMGCS2 3-Hydroxy-3-methylglutaryl-C
PLIN2 Perilipin 2
SLC25A20 Carnitine/acylcarnitine transloTo further characterize PPARa regulation, we performed a de
novo motif search using the chromatin sequences bound by PPARa
(Figure S3). We compared these motifs to two databases of tran-
scription factor binding sites, Jaspar and UniPROBE. As expected,
the most highly enriched motif corresponds well to the consensus
PPRE. We identiﬁed a long, high-ﬁdelity motif with no established
consensus (Figure S3, line 2). This putative site was found in 9
PPARa binding segments. We did not identify sites of known
PPARa coactivators within the segments.
3.2. Construction of a putative PPARa regulatory network
Nearly half of the differentially expressed genes we identiﬁed
neither contain a functional PPRE nor are bound by PPARa upon
treatment with a PPARa-selective agonist. We next turned to a
database of transcription factor-target associations from litera-
ture-curated high-throughput ChIP studies to identify possible
alternative pathways of regulation [36]. We screened the
transcription factors in the database to identify those that have
appreciable expression in liver tissue (see Table S1). We used a
constrained deﬁnition for promoter size to minimize false
positives: transcription factors were mapped to target genes if a
ChIP fragment for the transcription factor was within 10 kb
upstream or 1 kb downstream of the gene’s transcription start
site. Together, the ensemble of the differentially expressed genes
and these transcriptional regulators form a putative regulatory
network (Fig. 4). Because these data come from a diverse set of
experiments in a number of cell types, some of the interactions
may not be present in the context of PPARa biology in human
hepatocytes. However, this provisional network suggests the
scope of the regulatory landscape of the peroxisome proliferator
response.
The associations between PPARa–as well as other transcription
factors–and the target genes constitute a map of the regulatory
landscape of PPARa activation (Fig. 4). Here, nodes represent dif-
ferentially expressed target genes (circles; a target is represented
if it was identiﬁed as differentially expressed under any of the 25
dose/time conditions we considered) and transcription factors
(rectangles). Three distinct types of edges are represented in the
network (Figs. 1 and 4, Figure S4):
(i) Direct bound interactions: PPARa binds to its consensus
response elements (PPREs) at the promoters of target genes
(shown in blue lines extending from PPARa)
(ii) Indirect bound interactions: PPARa is bound to promoter
regions of target genes—but not to PPREs—presumably
through tethering with other transcription factors that
directly bind to the promoters of target genes (shown in
black lines extending from PPARa)primary hepatocytes upon treatment of GW7647. APOA2 and PLIN2 are
id not identify a PPRE at either of these locations. CYP1A1 do not bind
Reference
almitoyl [24]
[67]
[33]
[27]
1a, liver [25]
1b, muscle [68]
bfamily a, polypeptide 1 [35]
[69]
oenzyme A synthase 2 [70]
[34]
case [71]
A B
C D
Fig. 4. The PPARa regulatory landscape. (A) We inferred the transcriptional regulatory network of PPARa using an online database of promoter-transcription factor
interactions [36]. A target is featured if it was differentially expressed at one or more time or dose point. Circular nodes represent target genes; rectangular nodes are inferred
transcription factors. (B–D) Dose response of the peroxisome proliferator regulatory network at 24 h exposure. For each panel, genes are only shown if they are differentially
expressed at the indicated dose. Transcription factors are displayed if they are associated with at least one gene at the indicated dose. No genes were differentially expressed
at 0.001 or 0.01 lM at 24 h.
P.D. McMullen et al. / Chemico-Biological Interactions 209 (2014) 14–24 19(iii) Indirect unbound interactions: PPARa is not bound to the
promoter region of a differentially-expressed gene, which
is presumably activated or repressed by other TFs activated
by phosphorylation or crosstalk with alternative signaling
pathways (all remaining interactions).
3.3. Dose response of the PPARa regulatory network
The gene targets in Fig. 4A represent the union of all the differ-
entially expressed genes observed over all experimental conditions(5 doses; 5 time points). However, whether these targets are differ-
entially expressed at a particular condition (and to what extent) is
a function of both time and ligand dose. To visualize how these fac-
tors affect the PPARa regulatory network, we visualized the evolu-
tion of the network in response to dose after 24 h treatment
(Figs. 4B–D). To further demonstrate the dynamics of the network,
we have created an interactive web applet as a tool for exploring
the changes in the PPARa regulatory network in response to expo-
sure time and dose (http://www.thehamner.org/ppara_network).
We observed little gene expression change at any time point at
20 P.D. McMullen et al. / Chemico-Biological Interactions 209 (2014) 14–240.001 and 0.01 lM exposures. Genes regulated by PPARa binding
(either direct or indirect) were more likely to be differentially ex-
pressed at lower doses (Fig. 4B); thus PPARa seems to be activated
at lower doses compared to other transcription factors in the net-
work. We were unable to identify any major differences in the dose
response of the genes regulated by any transcription factor other
than PPARa.
3.4. Functional characterization of peroxisome proliferator response
The gene ontology (GO) is a collection of terms that ascribe bio-
logical context to cellular species. Its descriptions fall under three
domains: biological processes, cellular components, and molecular
functions. GO categories have proven instrumental in summarizing
the character of collections of genes, and are commonly used in the
interpretation of microarray and other high-throughput experi-
ments. The genes of an organism are annotated with GO terms
based on what is known of their biology.
To better understand the transcriptional program initiated upon
GW7647 treatment, we searched for commonalities among the
functions of the differentially expressed genes. We identiﬁed 22
GO biological process terms that are overrepresented in the differ-
entially expressed genes, relative to their occurrence in the gen-
ome at large [37] (Fig. 5 and S5). Interestingly, none of the GO
terms we identiﬁed are differentially enriched in the subset of
genes that are down-regulated upon treatment. This difference is
likely because the set of down-regulated genes is too small to af-
ford the statistical power necessary to establish a gene ontology
category as enriched.
Because GO is a collection of biological concepts that form a
hierarchical directed acyclic graph, terms that are near each other
in semantic meaning are also close to each other in the ontology.
As gene ontology annotations are curated from the literature and
from automated searches, the speciﬁc set of terms associated with
a gene is somewhat subjective. GO terms for two related genes
may not perfectly coincide, but will typically be nearby in the onto-
logical space. As such, we compiled the minimum network of gene
ontology terms that is required to connect the 22 GO terms over-
represented among the target genes (Fig. 5).
This process revealed that there are two semantic groups of
gene ontology terms that are enriched upon PPARa activation in
primary human hepatocytes: amino acid processing and fatty acid
processing (Fig. 5). This observation is consistent with what is
known about the role of PPARa in these processes [38]. These cat-
egories remain relatively consistent between dose and time fac-
tors; the principal difference being that higher doses and longer
exposure times yield a larger set of differentially expressed genes,
which make enriched GO categories easier to identify (hence, low-
er p-values). However, it was interesting to observe the enrichment
of ‘‘carboxylic acid transport’’ and ‘‘lipid localization’’ at high doses
of GW7647 (Fig. 5), suggesting the activation of dose-speciﬁc
mechanisms for coping with high concentrations of metabolites
produced after near-maximal activation of these various metabo-
lizing enzymes and lipid transport proteins.
3.5. The metabolic response to PPARa activation
Because of the important role of PPARa in sensing and respond-
ing to the lipid balance in the liver, we are also attempting to use
gene expression experiments to develop a better understanding
of the role of PPARa-responsive genes in fatty acid metabolism.
Though the set of genes regulated by PPARa is small, it consists
of nearly every major enzyme involved in lipid transport and
b-oxidation in both the mitochondria and the peroxisome (Fig. 6).
Interestingly, the regulation of the individual components of
b-oxidation depends upon their function and position in the b-oxi-dation cascade. Proteins involved in transport of fatty acids into the
mitochondria (CPT1A, CPT2, and SLC25A20) and fatty acid activa-
tion (ACADM and ACOX1) are among the direct bound targets. Also,
these proteins are up-regulated to a higher degree and up-regu-
lated at earlier exposure times compared to the other proteins in
the cascade (Figs. 2A and 6). This correlation indicates that direct
binding of PPARa governs aspects of the temporal and dose-depen-
dent organization of the metabolic response.4. Discussion
4.1. Identifying network structure
The nuclear receptor superfamily coordinates the genomic re-
sponse to a wide array of xenobiotic compounds by binding exog-
enous ligands and directly interacting with chromatin to promote
transcription. Our results suggest that this mechanism only ac-
counts for a small fraction of the response to peroxisome
proliferators.
The canonical model of PPARa-mediated response involves the
direct binding of activated PPARa to a well-established consensus
binding site. Indeed, many of the genes we identiﬁed as differen-
tially expressed upon GW7647 treatment participate in fatty acid
metabolism. However, we found that a substantial fraction of the
up-regulated genes were not bound by PPARa in primary hepato-
cytes or in HepG2 cells [14], indicating gaps in our understanding
of how peroxisome proliferators induce their genomic response.
4.2. Implications of indirect PPARa binding
Transcription factor tethering is a likely mechanism by which
PPARa could indirectly inﬂuence gene expression without binding
to a canonical PPRE [31,39–42]. Tethering has been implicated in
the regulation of about 25% of estrogen receptor-induced genes;
and 30% of glucocorticoid receptor binding to chromatin appears
to be indirect, likely by tethering to co-localized transcription
factors like RUNX1 and AP1 [39–42]. Also, while there are a vast
number of potential nuclear receptor binding sites across the
genome, only a small fraction of these sites is occupied, with an
even smaller number of sites likely contributing to functional gene
regulation in vivo [29,43,30]. This latter observation supports ap-
proaches like those shown in the present paper to combine gene
expression data from transcriptome proﬁling with genome-wide
location analysis to provide a more accurate picture of nuclear
receptor-mediated gene regulation.
Gene transcription via PPARa binding to a PPRE requires the
assembly of a coactivator complex [32]. The assembly of this com-
plex—rather than the translocation of PPARa to its cognate site—
may control gene expression [44]. This hypothesis is consistent
with the discordance between previously reported enhancement
of PPARa binding [14] and the ligand-activated gene expression
identiﬁed here. One of the genes down-regulated in our study
was TACC1. TACC1 modulates transcription associated with other
RXR-heterodimeric nuclear receptors (e.g., thyroid receptor and
retinoic acid receptor) and appears to be a scaffold protein provid-
ing the structure to build transcriptional complexes for these nu-
clear receptors. In HepG2 cells [22], PPARa indirectly bound this
gene (Figure S2). Our ChIP-seq study in primary hepatocytes did
not identify binding of PPARa to TACC1 and there is no evidence
of a functional PPRE in its promoter.
4.3. Understanding the nongenomic PPARa response
The relatively small fraction of genes bound by activated PPARa
suggests that non-genomic mechanisms control a major
AB
C
Fig. 5. Functional characterization of the peroxisome proliferator response. The network of gene ontology (GO) biological processes enriched for the union of genes showing
differential expression at least one dose or time point. The number of genes annotated with each term is reﬂected by node size and the signiﬁcance of the enrichment by node
color (hypergeometric test, GO terms with Benjamini-adjusted p-value <104 shown). Non-signiﬁcant nodes were included (white) as needed to complete the minimal
spanning tree. As expected, peroxisome proliferators have a profound effect on lipid and carboxylic acid metabolism processes. With increasing dose, the number of genes in,
and consequently, the signiﬁcance of, each functional annotation category increases (exposure time is 24 h). At high doses, fatty acid transport processes are activated (orange
trace).
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proliferators activate protein kinase cascades, leading to phosphor-
ylation of kinases related to the extracellular signal-regulatedkinase pathway, including Src [45], p38 [46], ERK1/2 [47–49],
MEK1 [48], Ras [45], and EGFR [50]. PPARa agonists may affect
ERK phosphorylation via a mechanism that depends on phosphati-
Fig. 6. The core machinery of mitochondrial and peroxisomal b-oxidation. Human genes with increased expression in response to the PPARa activator GW7647 are labeled in
red, blue, or green according to their regulatory mechanism. With few exceptions (most notably, the peroxisome bifunctional enzyme), every major enzyme involved in lipid
transport, oxidation, and electron capture is up-regulated in our study.
Table 2
Down-regulated genes with direct or indirect binding of PPARa.
Symbol Name
IGF1 Insulin-like growth factor 1
MCC Mutated in colorectal cancer
CPS1 Carbamoyl-phosphate synthase 1, mitochondrial
PTPRK Protein tyrosine phosphatase, receptor type K
NHSL1 NHS-like 1
RNF13 Ring ﬁnger protein 13
22 P.D. McMullen et al. / Chemico-Biological Interactions 209 (2014) 14–24dylinositol signaling [50]. Separately, several PPAR agonists have
been demonstrated to lead to the transient activation of p38
[45]. GW7647 and other PPARa agonists affect calcium signaling
in various cell types, including pancreatic b-cells [51] and eosino-
phils [52]. These various mechanisms contribute to activation of
transcription factors and induction of their target genes. While
the speciﬁc mechanisms by which non-genomic processes are ini-
tiated by peroxisome proliferators are not yet clear, they might ex-
plain expression changes in genes responsive to peroxisome
proliferators that have no demonstrated PPARa binding in their
promoter regions. We made preliminary attempts to determine
the role of kinase pathways in the PPARa network by examining
the effects of inhibition on gene expression in primary hepatocytes.
An alternative strategy with the human hepatocytes might be to
examine the kinase-mediated activation of PPARa itself to see if
the active kinase also phosphorylates key transcription factors
identiﬁed in the pathway (Fig. 4).
4.4. Network components other than regulators of fatty acid
metabolism
PPARa and the associated peroxisome proliferator response are
a normal part of hepatic biology. Persistent activation of thispathway in rats leads to hepatic responses, including hypertrophy,
cell proliferation and hepatocellular cancer [53]. These responses
are considered unlikely to occur in humans based on various stud-
ies of peroxisome proliferating compounds in human hepatocytes
that provide little evidence for enhancement of cell proliferation
[54,55]. In our gene expression analysis in human primary hepato-
cytes we saw no alteration in genes that would induce proliferation
at any of these times or concentrations. However, here were
changes in genes that might have a negative consequence for pro-
liferation. Of the down-regulated genes that are bound by PPARa
(Fig. 2A, Table 2), the two with the greatest change are IGF1 and
MCC. MCC (mutated in colorectal cancer) negatively regulates cell
cycle progression. IGF1 (Insulin like growth factor 1) protein is
P.D. McMullen et al. / Chemico-Biological Interactions 209 (2014) 14–24 23similar to insulin in structure and function. Down-regulation of
these genes and others may partially explain failure to cause pro-
liferation in human hepatocytes. CPS1 (carbamoyl-phosphate syn-
thase 1), which controls entry of nitrogen into the urea cycle, is
also down-regulated. This implies that PPARa mediates a negative
interplay between beta-oxidation and urea metabolism. Other
down-regulated genes also appear to have roles in growth and dif-
ferentiation. PTPRK (protein tyrosine phosphatase, receptor type K)
is a signal transducer that modulates epidermal growth factor
receptor activity in human keratinocytes [56].
Among the up-regulated genes that bind PPARa, there is a mix
of metabolism related genes, including PLIN1, PDK4, PEX11A,
PLA1A, CYP4A11, CYP1A1, HADHA, HADHB, PANK1, FABP1, and
genes with more diverse function. Some of these other genes are
involved in organelle formation and cell adhesion/integration—
LYRM1, MID1, and ITGB2. In addition, the network includes tran-
scription factors and cellular signaling proteins. CDK3 (cyclin-
dependent kinase 3) is a serine/threonine kinase involved in cell
cycle control. TXNIP (thioredoxin interacting protein), in addition
to modulating thioredoxin activity, is a transcriptional co-repres-
sor and cell cycle modulator [57]. We are now completing a similar
pathway analysis with rat primary hepatocytes. A comparison of
the regulatory networks between the two species with respect to
genes that indirectly bind PPARa should help identify aspects of
the network that either activate proliferative responses in the rat
or serve to limit proliferative responses in humans.
4.5. Dynamic properties of network activation
Our study moves away from providing a list of genes and their
connectivity to examining the transcriptional network associated
with nuclear receptor function. With several nuclear receptors that
are now known to be active as RXR heterodimers, responses appear
to include bimodal induction in rodent cells (cells appear either in
a basal or fully activated state) [58,59]. There is also hepatocyte
proliferation in the intact rat after treatment with agonists for
these nuclear receptors [60]. Both single-cell bimodal induction
and proliferation likely require ultrasensitive signaling motifs lead-
ing to bistable states for the cell transcriptional programs [61].
Candidate motifs for driving these bistable decision-making behav-
iors are MAP kinase cascades linked to coordinated activation of
groups of transcription factors. At this time, investigations are
ongoing to characterize the role of kinases, the phosphoproteomic
state of PPARa and implicated kinases, and the metabolic state of
hepatocytes in response to PPARa activation. With proliferation
driven by nuclear receptors, Src pathways associated with mem-
brane-tethered nuclear receptors are a common network structure
[62–66]. The change in gene expression proﬁles may be associated
with kinase pathways linked to receptor phosphorylation after li-
gand binding.
4.6. Human risk/safety assessments and toxicity pathways
A 2007 National Research Council (NRC) publication, Toxicity
Testing in the 21st Century; A Vision and A Strategy, proposed a
new safety assessment approach based on in vitro assays in human
cells relying on knowledge of modern biology and modes of action
of compounds in humans. The assays would examine speciﬁc path-
ways or networks (such as with PPARa signaling in liver) without
regard to speciﬁc apical responses seen in toxicity tests in animals
or from human disease or epidemiology. The NRC report referred to
testing responses of toxicity pathways, which are simply normal
biochemical pathways that could lead to adverse consequences if
activated or suppressed at a sufﬁcient level over time. The larger
suite of nuclear receptor pathways provides important targets for
toxicity and good case studies for looking at the approachesneeded to move to in vitro platforms for risk assessment. Our ap-
proach here is a ﬁrst step to outline the network for PPARa and
we expect to extend it to other nuclear receptor pathways follow-
ing further progress in establishing pathway dynamics for bimodal
patterns of the hepatocyte gene expression proﬁles in the presence
and absence of ligand. With PPARa, an interesting modality for
pathway identiﬁcation and dose response would be metabolomics
applied with an active biological ligand whose concentration
would be reduced by the PPARa pathway.
For some nuclear receptor pathways, the endogenous ligand or
class of ligands is well understood. PPARa binds a number of rep-
resentative endogenous fatty acids and cannabinoids. For many
other nuclear receptor pathways—CAR, AhR, PXR, etc.—that in-
crease Phase I, II, and III enzymatic pathways, endogenous ligand
are not as well established. Presumably, these pathways map the
signal from an endogenous ligand to a response that is related to
the quantity of that ligand, much like fatty acids activate PPARa
to induce b-oxidation. Applied to other nuclear receptor toxicity
pathways, we expect our approach to reveal the endogenous role
of the pathway and shed light on the native ligand of the receptor
system.
Conﬂict of interest
None.
Acknowledgements
The authors thank the American Chemistry Council Long Range
Initiative (ACC-LRI), Dow Chemical, Dow Corning, ExxonMobil
Foundation, Agilent Foundation, CropLife America, Illumina, Inc.,
and the United States Environmental Protection Agency STAR
program (Grant #R835000) for their support of this work.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.cbi.2013.11.006.
References
[1] M.E. Andersen, D. Krewski, Toxicity testing in the 21st century: bringing the
vision to life, Toxicol. Sci. 107 (2) (2009) 324–330.
[2] M.E. Andersen, D. Krewski, The vision of toxicity testing in the 21st century:
moving from discussion to action, Toxicol. Sci. 117 (1) (2010) 17–24.
[3] NRC, Toxicity Testing in the 21st Century: A Vision and a Strategy, The National
Academies Press, Washington, DC, 2007.
[4] M.V. Chakravarthy et al., Identiﬁcation of a physiologically relevant
endogenous ligand for PPARalpha in liver, Cell 138 (3) (2009) 476–488.
[5] P. Lefebvre et al., Sorting out the roles of PPARa in energy metabolism and
vascular homeostasis, J. Clin. Invest. 116 (3) (2006) 571–580.
[6] S. Mandard, M. Müller, S. Kersten, Peroxisome proliferator-activated receptor a
target genes, Cell. Mol. Life Sci. 61 (4) (2004) 393–416.
[7] L. Michalik, W. Wahli, PPARs mediate lipid signaling in inﬂammation and
cancer, PPAR Res. (2008). Article ID 134059.
[8] F. Zandbergen, J. Plutzky, PPARa in atherosclerosis and inﬂammation, Biochim.
Biophys. Acta. Mol. Cell Biol. Lipids 1771 (8) (2007) 972–982.
[9] S.J. Bensinger, P. Tontonoz, Integration of metabolism and inﬂammation by
lipid-activated nuclear receptors, Nature 454 (7203) (2008) 470–477.
[10] J.K. Reddy, D.L. Azarnoff, C.E. Hignite, Hypolipidaemic hepatic peroxisome
proliferators form a novel class of chemical carcinogens, Nature 283 (5745)
(1980) 397–398.
[11] J.K. Reddy, M.S. Rao, D.E. Moody, Hepatocellular carcinomas in acatalasemic
mice treated with Nafenopin, a hypolipidemic peroxisome proliferator, Cancer
Res. 36 (4) (1976) 1211–1217.
[12] J.D. Tugwood et al., The mouse peroxisome proliferator activated receptor
recognizes a response element in the 50 ﬂanking sequence of the rat acyl CoA
oxidase gene, EMBO J. 11 (2) (1992) 433–439.
[13] C. Dreyer et al., Control of the peroxisomal beta-oxidation pathway by a novel
family of nuclear hormone receptors, Cell 68 (5) (1992) 879–887.
[14] D.L. van der Meer et al., Proﬁling of promoter occupancy by PPARalpha in
human hepatoma cells via ChIP-chip analysis, Nucleic Acids Res. 38 (9) (2010)
2839–2850.
24 P.D. McMullen et al. / Chemico-Biological Interactions 209 (2014) 14–24[15] M.B. Rosen et al., Gene proﬁling in the livers of wild-type and PPARalpha-null
mice exposed to perﬂuorooctanoic acid, Toxicol. Pathol. 36 (4) (2008) 592–
607.
[16] R.K. Semple et al., A dominant negative human peroxisome proliferator-
activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor
and inhibits signaling through all PPAR isoforms, Endocrinology 146 (4) (2005)
1871–1882.
[17] P.J. Brown et al., Identiﬁcation of a subtype selective human PPARalpha agonist
through parallel-array synthesis, Bioorg. Med. Chem. Lett. 11 (9) (2001) 1225–
1227.
[18] R.A. Irizarry et al., Summaries of affymetrix GeneChip probe level data, Nucleic
Acids Res. 31 (4) (2003) e15.
[19] Y. Benjamini, Y. Hochberg, Controlling the false discovery rate – a practical and
powerful approach to multiple testing, J. Royal Stat. Soc. B Method. 57 (1)
(1995) 289–300.
[20] H. Li, R. Durbin, Fast and accurate short read alignment with Burrows–Wheeler
transform, Bioinformatics 25 (14) (2009) 1754–1760.
[21] Y. Zhang et al., Model-based analysis of ChIP-Seq (MACS), Genome Biol. 9 (9)
(2008) R137.
[22] P. Machanick, T.L. Bailey, MEME-ChIP: motif analysis of large DNA datasets,
Bioinformatics 27 (12) (2011) 1696–1697.
[23] T.L. Bailey et al., MEME SUITE: tools for motif discovery and searching, Nucleic
Acids Res. 37 (Web Server issue) (2009) W202–8.
[24] U. Varanasi et al., Identiﬁcation of a peroxisome proliferator-responsive
element upstream of the human peroxisomal fatty acyl coenzyme A oxidase
gene, J. Biol. Chem. 271 (4) (1996) 2147–2155.
[25] C. Mascaro et al., Control of humanmuscle-type carnitine palmitoyltransferase
I gene transcription by peroxisome proliferator-activated receptor, J. Biol.
Chem. 273 (15) (1998) 8560–8563.
[26] L. Napal, P.F. Marrero, D. Haro, An intronic peroxisome proliferator-activated
receptor-binding sequence mediates fatty acid induction of the human
carnitine palmitoyltransferase 1A, J. Mol. Biol. 354 (4) (2005) 751–759.
[27] M. Nagasawa et al., Identiﬁcation of a functional peroxisome proliferator-
activated receptor (PPAR) response element (PPRE) in the human
apolipoprotein A-IV gene, Biochem. Pharmacol. 78 (5) (2009) 523–530.
[28] M. Rakhshandehroo et al., Comparative analysis of gene regulation by the
transcription factor PPARalpha between mouse and human, PLoS ONE 4 (8)
(2009) e6796.
[29] J.S. Carroll et al., Chromosome-wide mapping of estrogen receptor binding
reveals long-range regulation requiring the forkhead protein FoxA1, Cell 122
(1) (2005) 33–43.
[30] J.S. Carroll et al., Genome-wide analysis of estrogen receptor binding sites, Nat.
Genet. 38 (11) (2006) 1289–1297.
[31] C.L. George, S.L. Lightman, S.C. Biddie, Transcription factor interactions in
genomic nuclear receptor function, Epigenomics 3 (4) (2011) 471–485.
[32] N. Viswakarma et al., Coactivators in PPAR-Regulated Gene Expression, PPAR
Res. 2010 (2010).
[33] N. Vu-Dac et al., Fibrates increase human apolipoprotein A-II expression
through activation of the peroxisome proliferator-activated receptor, J. Clin.
Invest. 96 (2) (1995) 741–750.
[34] P. Targett-Adams et al., A PPAR response element regulates transcription of the
gene for human adipose differentiation-related protein, Biochim. Biophys. Acta
1728 (1–2) (2005) 95–104.
[35] E. Seree et al., Evidence for a new human CYP1A1 regulation pathway
involving PPAR-alpha and 2 PPRE sites, Gastroenterology 127 (5) (2004) 1436–
1445.
[36] V. Matys et al., TRANSFAC: transcriptional regulation, from patterns to proﬁles,
Nucleic Acids Res. 31 (1) (2003) 374–378.
[37] W. Huang da, B.T. Sherman, R.A. Lempicki, Bioinformatics enrichment tools:
paths toward the comprehensive functional analysis of large gene lists, Nucleic
Acids Res. 37 (1) (2009) 1–13.
[38] M. Rakhshandehroo et al., Comprehensive analysis of PPARalpha-dependent
regulation of hepatic lipid metabolism by expression proﬁling, PPAR Res. 2007
(2007) 26839.
[39] J.D. Stender et al., Genome-wide analysis of estrogen receptor a DNA binding
and tethering mechanisms identiﬁes Runx1 as a novel tethering factor in
receptor-mediated transcriptional activation, Mol. Cell. Biol. 30 (16) (2010)
3943–3955.
[40] T.E. Reddy et al., Genomic determination of the glucocorticoid response reveals
unexpected mechanisms of gene regulation, Genome Res. 19 (12) (2009)
2163–2171.
[41] A.Y. So et al., Determinants of cell- and gene-speciﬁc transcriptional regulation
by the glucocorticoid receptor, PLoS Genetics 3 (6) (2007).
[42] N. Heldring et al., Estrogen receptors: how do they signal and what are their
targets, Physiol. Rev. 87 (3) (2007) 905–931.
[43] V. Bourdeau et al., Genome-wide identiﬁcation of high-afﬁnity estrogen
response elements in human and mouse, Mol. Endocrinol. 18 (6) (2004) 1411–
1427.[44] C. Tudor et al., Association with coregulators is the major determinant
governing peroxisome proliferator-activated receptor mobility in living cells, J.
Biol. Chem. 282 (7) (2007) 4417–4426.
[45] O.S. Gardner et al., Dependence of peroxisome proliferator-activated receptor
ligand-induced mitogen-activated protein kinase signaling on epidermal
growth factor receptor transactivation, J. Biol. Chem. 278 (47) (2003) 46261–
46269.
[46] T. Teruel et al., Rosiglitazone and retinoic acid induce uncoupling protein-1
(UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal
primary brown adipocytes, J. Biol. Chem. 278 (1) (2003) 263–269.
[47] B.J. Ledwith et al., Growth regulation by peroxisome proliferators: opposing
activities in early and late G1, Cancer Res. 56 (14) (1996) 3257–3264.
[48] C.L. Rokos, B.J. Ledwith, Peroxisome proliferators activate extracellular signal-
regulated kinases in immortalized mouse liver cells, J. Biol. Chem. 272 (20)
(1997) 13452–13457.
[49] C.J. Pauley, B.J. Ledwith, C. Kaplanski, Peroxisome proliferators activate growth
regulatory pathways largely via peroxisome proliferator-activated receptor
alpha-independent mechanisms, Cell. Signal. 14 (4) (2002) 351–358.
[50] B.J. Mounho, B.D. Thrall, The extracellular signal-regulated kinase pathway
contributes to mitogenic and antiapoptotic effects of peroxisome proliferators
in vitro, Toxicol. Appl. Pharmacol. 159 (2) (1999) 125–133.
[51] A.B. Ropero et al., Rapid non-genomic regulation of Ca2+ signals and insulin
secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans, J.
Endocrinol. 200 (2) (2009) 127–138.
[52] S.G. Smith et al., The effect of PPAR agonists on the migration of mature and
immature eosinophils, PPAR Res. 2012 (2012) 235231.
[53] R.C. Cattley, Peroxisome proliferators and receptor-mediated hepatic
carcinogenesis, Toxicol. Pathol. 32 (Suppl 2) (2004) 6–11.
[54] J.E. Klaunig et al., PPARalpha agonist-induced rodent tumors: modes of action
and human relevance, Crit. Rev. Toxicol. 33 (6) (2003) 655–780.
[55] F.J. Gonzalez, Y.M. Shah, PPARalpha: mechanism of species differences and
hepatocarcinogenesis of peroxisome proliferators, Toxicology 246 (1) (2008)
2–8.
[56] Y. Xu et al., Receptor-type protein-tyrosine phosphatase-kappa regulates
epidermal growth factor receptor function, J. Biol. Chem. 280 (52) (2005)
42694–42700.
[57] S.H. Han et al., VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin
D3 inhibits tumor cell growth by blocking cell-cycle progression, Oncogene 22
(26) (2003) 4035–4046.
[58] R.G. Bars et al., Induction of cytochrome P-450 in cultured rat hepatocytes. The
heterogeneous localization of speciﬁc isoenzymes using
immunocytochemistry, Biochem. J. 262 (1) (1989) 151–158.
[59] R. Sarangapani et al., Dose–response modeling of cytochrome p450 induction
in rats by octamethylcyclotetrasiloxane, Toxicol. Sci. 67 (2) (2002) 159–172.
[60] J.D. Oliver, R.A. Roberts, Receptor-mediated hepatocarcinogenesis: role of
hepatocyte proliferation and apoptosis, Pharmacol. Toxicol. 91 (1) (2002) 1–7.
[61] Q. Zhang, S. Bhattacharya, M.E. Andersen, Ultrasensitive response motifs: basic
ampliﬁers in molecular signalling networks, Open Biol. 3 (4) (2013) 130031.
[62] A. Piskunov and C. Rochette-Egly, MSK1 and Nuclear receptors signaling, in:
MSKs, J.S.C. Arthur (Ed.), Landes Biosci, 2013.
[63] F. Zassadowski et al., Regulation of the transcriptional activity of nuclear
receptors by the MEK/ERK1/2 pathway, Cell. Signal. 24 (12) (2012) 2369–2377.
[64] L. Kang et al., Involvement of estrogen receptor variant ER-alpha36, not GPR30,
in nongenomic estrogen signaling, Mol. Endocrinol. 24 (4) (2010) 709–721.
[65] A.W. Norman, M.T. Mizwicki, D.P. Norman, Steroid-hormone rapid actions,
membrane receptors and a conformational ensemble model, Nat. Rev. Drug
Discov. 3 (1) (2004) 27–41.
[66] X. Yang et al., Novel membrane-associated androgen receptor splice variant
potentiates proliferative and survival responses in prostate cancer cells, J. Biol.
Chem. 286 (41) (2011) 36152–36160.
[67] S. Mandard et al., The direct peroxisome proliferator-activated receptor target
fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood
plasma as a truncated protein that is increased by fenoﬁbrate treatment, J.
Biol. Chem. 279 (33) (2004) 34411–34420.
[68] G.S. Yu, Y.C. Lu, T. Gulick, Co-regulation of tissue-speciﬁc alternative human
carnitine palmitoyltransferase Ibeta gene promoters by fatty acid enzyme
substrate, J. Biol. Chem. 273 (49) (1998) 32901–32909.
[69] H. Poirier et al., Differential involvement of peroxisome-proliferator-activated
receptors alpha and delta in ﬁbrate and fatty-acid-mediated inductions of the
gene encoding liver fatty-acid-binding protein in the liver and the small
intestine, Biochem. J. 355 (Pt. 2) (2001) 481–488.
[70] M.H. Hsu et al., Identiﬁcation of peroxisome proliferator-responsive human
genes by elevated expression of the peroxisome proliferator-activated
receptor alpha in HepG2 cells, J. Biol. Chem. 276 (30) (2001) 27950–27958.
[71] K. Tachibana et al., Regulation of the human SLC25A20 expression by
peroxisome proliferator-activated receptor alpha in human hepatoblastoma
cells, Biochem. Biophys. Res. Commun. 389 (3) (2009) 501–505.
